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Abstract 
The Kunitz-type protease inhibitor domain from a recently identified homolog of the Alzheimer amyloid precursor protein (APPH KPI) was 
expressed in yeast, purified and characterized. Its inhibition profile towards several serine proteases was studied and compared to that of APP KPI, 
the Kunitz domain from the Alzheimer amyloid precursor protein. APPH KPI was shown to inhibit proteases with trypsin-like specificity with an 
inhibitor profile resembling that of the APP KPI domain. The KPI domains from APP and APPH inhibited trypsin (K, = 0.02 nM), and plasma 
kallikrein (K, = 86 nM) with approximal equal affinity. In comparison to APP KPI (K, = 82 nM) the KPI domain of the homolog, APPH KPI, 
(K, = 8.8 nM) was a more potent inhibitor of glandular kallikrein. APPH KPI was a less potent inhibitor of chymotrypsin than APP KPI (K, = 78 
nM as compared to K, = 6 nM), plasmin (K, = 81 nM as compared to 42 nM), and factor XI, (K, = 14 nM as compared to K, = 0.7 nM). The affinity 
of factor XI, for APPH KPI is sufficiently high to allow for an interaction in the blood. It is, however, well possible that the physiological protease 
ligand for the receptor-like APPH protein has yet to be identified. 
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1. Introduction 
The amyloid B-protein which accumulates in senile 
plaques of patients with Alzheimer’s disease is a 42- 
amino-acid peptide which is derived by proteolysis from a 
much larger precursor known as the Amyloid Precursor 
Protein (APP). Several alternative molecular forms of 
the precursor exist, apparently due to a combination of 
alternative mRNA splicing and proteolytic cleavage. Re- 
cent studies have shown that the full-length APP cDNA 
can be processed by mammalian cells in culture to pro- 
duce both the amyloid peptide and also a truncated, 
secreted form of the extracellular protein domain [1,2]. 
The cDNA for a similar molecule, called Amyloid 
Precursor Protein Homolog (APPH), has recently been 
identified and cloned in this laboratory from human pla- 
centa [3]. Like APP, APPH appears to have a domain 
organization resembling a cell-surface receptor with a 
very large extracellular segment, a single trans-mem- 
brane domain, and a short intracellular domain. The 
*Corresponding author. Fax: (45) (31) 682 800. 
Abbreviations: APP, amyloid precursor protein; APPH, amyloid pre- 
cursor protein homolog; KPI, Kunitz-type protease inhibitor; BPTI, 
bovine pancreatic trypsin inhibitor. 
extracellular segment of both proteins contains a ‘Cys- 
rich’ and a Kunitz-type protease inhibitor (KPI) domain. 
The highly conserved regions of the protein suggest sim- 
ilarity of function for APP and APPH within their rela- 
tive biological contexts, although the normal functions 
of these proteins are presently unknown. Some aspects 
of possible function can be inferred from the inhibitory 
properties of the KPI domain of APP, which has been 
studied both as the truncated, secreted form of the native 
molecule [4-g], and also as an individual KPI domain 
expressed in COS-1 cells [9], bacterial [lO,l l] and yeast 
[ 121 systems. 
In order to study the potential protease inhibitor prop- 
erties of the APPH KPI domain, we have employed a 
yeast expression system shown previously to be highly 
efficient in the synthesis and secretion of KPI domains 
[ 131. The APPH KPI domain was expressed in high yield, 
purified and the inhibition profile compared to that of 
APP KPI domain and BPTI produced by the same ex- 
pression system. 
2. Materials and methods 
2. I. Substrates 
Chromogenic substrates H-o-Val-Leu-Lys-pNA; MeO-Suc-Arg- 
Pro-Tyr-pNA; H-o-Val-Leu-Arg-pNA; CGlu-Gly-Arg-pNA; H-o-Ile- 
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Pro-Arg-pNA; <Glu-Pro-Arg-pNA; H-o-Pro-Phe-Arg-PNA; H-D- 
Phe-Pip-Arg-pNA were purchased from Chromogenix (Moelndal. 
Sweden), MeO-CO-CHA-Gly-Arg-pNA was from NycoMed (Oslo, 
Norway), and MeO-Sue-Ala-Ala-Pro-Val-pNA; Suc-Ala-Ala-Pro-Phe- 
pNA were from Sigma (St.Louis, MO). The fluorogenic substrate Boc- 
Glu(OBzl)-Ala-Arg-MCA was from Peptide Institute (Osaka, Japan). 
2 2. Proteases 
Porcine trypsin, chymotrypsin, and human thrombin was from Novo 
Nordisk (Bagsvaerd, Denmark). Glandular kallikrein was from Sigma 
(St.Louis, MO). Human plasmin and plasma kallikrein was from Kabi 
(Stockholm, Sweden) and uPA was from Serono (Freiburg, Germany). 
Recombinant proteins of human tPA, protein C, and factor VII, were 
from Novo Nordisk (Bagsvaerd, Denmark). Human leukocyte lastase 
and cathepsin G were purified according to the procedure described by 
Baugh and Travis [14]. Human factor X,, factor XI, and factor XII, 
were generous gifts from Dr W. Kisiel (Albuquerque, NM), Dr K. 
FuJikawa (Seattle, WA) and Dr I. Schousboe (Copenhagen, Denmark), 
respectively. 
2.3. General methods 
Standard DNA techniques were carried out as described [15]. Syn- 
thetic ohgonucleotides were prepared on an automatic DNA synthe- 
sizer (380B. Applied Biosystems) using commercially available rea- 
gents. DNA sequence determinations were performed by the dideoxy 
chain-termination technique [16]. Polymerase chain reactions (PCR) 
were performed on a DNA Thermal Cycler (Perkin-Elmer-Cetus) using 
a commercial kit (GeneAmp, Perkin-Elmer-Cetus). 
2 4. Construction of the APPH KPI secreting yeast strain 
1 ,ug of human genomic DNA (Clontech, Palo Alto, CA) was used 
as a template in a PCR reaction containing 100 pmol each of the 
primers 1 (GCTGAGAGATTGGAGAAGAGAGATGTCAAAGCT- 
GTCTGCTCCC) and 2 (AGTTGGTCTAGATTACGCTTTACA- 
CACAGCCATAC) (Fig. 1). The 3’ half of primer 1 is identical to the 
N-terminal encoding part of the APPH KPI gene [3]. and the 5’ half is 
identical to the C-terminal encoding part of the previously described 
hybrid yeast leader [17]. Primer 2 is complementary to the C-terminal 
part of the APPH KPI domain and carries a 5’ extension containing a 
translation stop codon followed by an Xbal site. 
The PCR reaction was performed in a 100 yl volume and the follow- 
ing cycle: 94°C for 20 s, 50°C for 20 s, and 72°C for 30 s. After 19 cycles 
a final cycle was performed in which the 72°C step was maintained for 
10 min. The PCR product, a 210 bp fragment, was isolated by electro- 
phoresis on a 2% agarose gel. _ 
The APPH KPI DNA fragment was fused m-frame to the hvbrid 
leader gene by overlay extenzon PCR [18]. The product was digested 
with EcoRI and Xbal and isolated as a 412 bp DNA fragment. This 
fragment was ligated to the 9.3 kb Ncol-XbaI fragment and the 1.6 kb 
NcoIIEcoRI fragment both from the S. cerevisiae-E. coli shuttle vector 
pMT-636 [17]. The ligation mixture was transformed into E. coli strain 
MT-I 72, and the APPH KPI expression plasmid, KFN-1953, was iso- 
lated. Plasmid pKFN-1953 was transformed into S. cerevisiae strain 
MT-663 by selection for growth on glucose as the sole carbon source. 
One transformant, KFN-1963, was selected for fermentation. 
2 5. Construction of the APP KPI secretmg yeast strain 
PCR cloning of APP KPI 3-58 (BPTI numbering) was performed 
essentially as described above from human genomic DNA by substitut- 
ing primer 1 with (GCTGAGAGATTGGAGAAGAGAGAGGTGT- 
GCTCTGAAC) and primer 2 with (CTGCTATCTAGATTAGGCG- 
CTGCCACACACGGC). The expression plasmid was transformed 
into S. cerevisiae and one transformant, KFN-1653. was selected for 
fermentation. 
2.6. Fermentation 
The transformants described above were cultivated at 30°C for 4 
days in yeast peptone dextrose (YPD) medium [19] to an OD 650 nm 
value of 30. At the end of the fermentation the pH was adjusted to 3.0 
by addition of cont. H,PO,. The supernatants were isolated after cen- 
trifugation. 
2.7. Purl$catlon 
A total of approximately 1 litre fermentation supernatant was ad- 
justed to pH 8.0 by addition of solid Tris-HCl to 50 mM and titration 
with 4 M NaOH. The supematant was filtered before it was applied to 
a column of bovine trypsin immobilized to CNBr-activated Sepharose 
(350 mg bovine trypsin pr 35 ml gel). The column was subsequently 
washed with 150 ml 0.1 M Tris-HCI, 0.5 M NaCI, pH 8.0 and 150 ml 
0.01 M Tris-HCI. pH 8.0 before bound material was eluted with 200 
ml 0.2 M glvcine-HCl pH 3.0. Fractions of 10 ml was collected and -_ 
analyzed by reverse phase HPLC. Protein containing fractions were 
combined. This pool was applied to a preparative reverse-phase HPLC 
column. (Vydac 214TP510, The Separations Group. Hesperia CA) 
equilibrated with 5% B and 95%A, where eluent A was 0.1% TFA m 
H?O and eluent B was 0.07% TFA in acetonitrile. Flow rate was main- 
tamed at 4 ml/mm. Following the application, the column was washed 
with 5% B until baseline was achieved at 214 nm. Gradient elution with 
fraction collection was then performed from 5 to 85% B over 80 min. 
Fractions containing UV absorbing material were analyzed by reverse 
phase HPLC (Vydac 214TP54) and combined to give pools of chroma- 
tographically pure material. Removal of solvent was obtained by vac- 
uum centrifugation. The concentration and total yield of inhibitor in 
the major pools was estimated by reverse phase HPLC analysis and by 
comparison to a BPTI standard. The final preparations were character- 
ized by electrospray mass spectrometry (SCIEX API 111). 
2.8. Trypsin titration by APPH KPI, APP KPI and BPTI 
Trypsin (8 nm) was incubated with various concentrations of mhib- 
itor for 15 min. Substrate (0.6 mM H-D-Val-Leu-Lys-pNA) was then 
added. and residual activity was measured. The reaction took place in 
microtiter wells m 100 mM NaCI, 50 mM Tris-HCI, 0.01% Tween 80. 
pH 7.4 at 25°C in a total volume of 300 ~1. Amidolytic activity was 
measured as the change in absorbance at 405 nm. 
2.9. Inhtbition kmeties 
Measurements of inhibition kinetics were performed in microtiter 
wells essential1 as described for the trypsin inhibition experiment. Ami- 
dolytic activity was measured as the change m absorbance at 405 nm 
or as the change in fluorescence Em. at 460 nm (Ex. 380 nm). The 
apparent inhibition constant, K,‘, was determined using the non-linear 
regression data analysis program Enzfitter (Biosoft, Cambridge, UK). 
K, values were obtained by correcting for the effect of substrate accord- 
ing to the equation. 
K, = K,‘I( 1 +[S]IK,,,) 
3. Results 
Two inhibitor pools were obtained from the final step 
of the APPH KPI purification procedure. The major 
pool contained 12.1 mg inhibitor. Electrospray mass 
ATAAACGACCAAAAGAATGAAGGCTGTTTTCTGTTTTCTTGG~TTGTCCTTGATCGGATTCTGCTG 
MKAVFLVLSLIGFCW 
GGCCCAACCAGTCACTGGCGATGAATCATCATCTGTTGAGA~CCGG~GAGTCTCTGATCAT 
AQPVTGDESSVEIPEESLII 
CGCTGAAAACACCACTTTGGCTAACGTCGTCGCCATGG~GAGAGATTGGAGMGAGAGATGT 
AENTTLANVAMAERLEKRtDV 
1-r 
CAAAGCTGTCTGCTCCCAGGAGGCGATGACGGGGCCCTGCCGGGCCGTGATGCCTCGTTG 
KAVCSQ EAYTGPCRAVYPRH 
GTACTTCGACCTCTCCAAGGGAAAGTGCGTGCGTGCG~TTATATATGGTGGCTGCGGCGGC~ 
YFDLSXGKCVRFIYGGCGGN 
-2 XbaI 
CAGGRACAATTTTGAGTCTGAGGATTATT~GCTGTGTGT~GCGTMTCTAGA 
RNNFESEDYCUAVCXA 
Fig. 1. Nucleotide sequence and corresponding amino acid sequence of 
the 412 bp EcoRI-Xbal fragment encoding the leader - APPH KPI 
fusion protein. The Kex 2 processing site is indicated by a vertical 
arrow. The amino acid sequence of the secreted APPH KPI domain is 
shown m bold letters. The underlined sequences correspond to the PCR 
primers with horizontal arrows indicating the direction 
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spectrometry analysis revealed a molecular mass of 
6459.0 Da in agreement with the theoretical calculated 
mass of the inhibitor (6458.4 Da) were obtained. How- 
ever, mass spectrometry analysis also demonstrated that 
a molecular form with an additional 162 mass unit was 
present in the preparation. This is the molecular weight 
of a hexose unit and strongly indicated that a proportion, 
approximately 20%, of the inhibitor was 0-glycosylated 
with a single mannose residue. This partially glycosyl- 
ated preparation was used for characterisation of the 
APPH KPI inhibition. Glycosylations with typically 1 to 
4 mannose residues in 0-glycosidic linkage to serine or 
threonine is a common posttranslational modification in 
yeast [20]. Both serine (3 residues) and threonine (1 resi- 
due) are present in APPH KPI. However, potential gly- 
cosylation sites are not present in the protease contact 
region of APPH KPI, and therefore probably of no sig- 
nificance to inhibitory interactions. 
A molecular mass of 6477.0 Da was found for the 
dominating molecular species in the smaller, second pool 
from the APPH KPI purification procedure (not shown). 
The result suggests that one of three methionine residues 
in APPH KPI was oxidized to its sulfoxide. One 
methionine is present in the protease contact region (P4’) 
and preliminary results indicated that this specific resi- 
due was relatively susceptible to oxidation. The modifi- 
cation might affect the functional properties of the inhib- 
itor, and the preparation was not used for the inhibition 
experiments reported in the present paper. A molecular 
form with an additional 162 mass units, probably repre- 
senting an oxidized- and 0-glycosylated form of the in- 
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hibitor, was also present as a fraction of this inhibitor 
pool. 
APP KPI was expressed in higher yield than APPH 
KPI and about 100 mg was purified from one litre of 
yeast fermentation supernatant. Only a single molecular 
species of 6152.2 Da was found in the final preparation 
in accordance with a calculated molecular mass of 6153.8 
Da for APP KPI. No glycosylation of APP KPI was 
observed by mass spectrometric analysis. As was the case 
for APPH KPI, a separate, smaller pool obtained from 
the HPLC fractionation contained, however, mainly ox- 
idized APP KPI. This preparation was not further char- 
acterized. 
BPTI was also expressed in high yield, and the final 
preparation was homogenous when analyzed by reverse- 
phase HPLC and mass spectrometry. A molecular mass 
of 65 12.0 Da was obtained for the recombinant BPTI in 
accordance with the theoretical value of 6511.5 Da. 
All three KPI proteins inhibited trypsin with a high 
affinity. This property could be used to obtain a func- 
tional inhibitor concentration from a trypsin inhibition 
(titration) experiment (results not shown). These results, 
and the presence of a lysinelarginine in the Pl position, 
indicated that the target enzyme should be found among 
the serine proteases with trypsin-like substrate specific- 
ity. 
Fig. 2 shows a direct comparison of the inhibition 
profiles for the KPI domains of APP, APPH and BPTI 
with proteases involved in digestion, coagulation, fibri- 
nolysis and immune system reactions. The figure shows 
per cent inhibition at 1.0*10-6 M of the inhibitor. Pro- 
100 
Fig. 2. Inhibition profile of APPH KPI, APP KPI and BPTI: inhibition in% at 1 PM inhibitor. The inhibition was measured as the residual activity 
obtained after incubation of the protease with inhibitor for 30 min. The protease and its respective substrate were present in the reaction mixture 
as follows: 8 nM trypsin, 0.6 mM n-Val-Leu-Lys-pNA; 2.5 nM chymotrypsin, 0.6 mM MeO-Sue-Arg-Pro-Tyr-pNA; 1 U/ml glandular kallikrein, 
n-Val-Leu-Arg-pNA; 10 nM plasmin, 0.6 mM o-Val-Leu-Lys-pNA; 5 nM uPA, 0.6 mM CGlu-Gly-Arg-pNA; 5 nM tPA, 0.6 mM o-Ile-Pro-Arg-pNA; 
5 nM protein C,, 0.6 mM <Glu-Pro-Arg-pNA; 3 nM plasma kallikrein, 0.6 mM n-Pro-Phe-ArgpNA; 30 nM factor XII,, 0.6mM o-Pro-Phe-Arg-pNA; 
1 nM factor XI,, 0.12 mM Boc-Glu(OBzl)-Ala-Arg-MCA; 300 mM factor VII,, 0.6 mM o-Ile-Pro-Arg-pNA; 0.2 NIHU/ml thrombin, 0.6 mM 
o-Phe-Pip-Arg-pNA: 10 nM leukocyte elastase, MeO-Sue-Ala-Ala-Pro-Val-pNA; 50 nM cathepsin G, 0.6 mM Sue-Ala-Ala-Pro-Phe-pNA. 
+ 
f 
20 40 60 
[Inhibitor] 
Fig. 3. Factor XI, inhibition by APPH KPI, APP KPI and BPTI. 
Factor XI, (1 nM) was incubated with various concentrations of inhib- 
itor for 15 min. Substrate (0.12 mM Boc-Glu(OBzI)-Ala-Arg-MCA) 
was then added, and the residual activity was measured by fluorometry 
(Ex: 380 nm; Em: 460 nm). The activity was measured in arbitrary 
fluorescence units per min. Curve a: BPTI; curve b: APPH KPI: curve 
c: APP KPI. 
found inhibition by APPH KPI under these conditions 
was found with trypsin, chymotrypsin, plasmin, factor 
XI,, and plasma- and glandular kallikrein. 
The inhibition kinetics with these proteases were meas- 
ured, and the results (K, values) are summarized in Table 
1. APPH is a more potent inhibitor of glandular kal- 
likrein than APP and binds with a ten fold higher affin- 
ity. APP, on the other hand, binds to chymotrypsin with 
a tenfold higher affinity than that of APPH. 
APP is a very potent inhibitor of factor XI,, and this 
property may be a clue to its physiological function [5,6]. 
It was therefore of interest o study the inhibition of this 
protease by APPH KPI in further detail. Fig. 3 shows the 
inhibition of factor XI, by APP, APPH and BPTI. The 
Table 1 
K, values for the inhibition by APPH KPI and APP KPI 
Protease (concentration) 
Trypsin (0.11 nM) 
Chymotrypsin (2.5 nM) 
Plasmin (10 nM) 
Pl. Kallikrein (3 nM) 
Cl. Kallikrein (1 U/ml) 
Factor XIa (1 nm) 
APPH KPI APP KPI 
K, (nM) K, (nM) 
0.02 0.02 
78 6 
81 42 
91 82 
8.8 82 
14 0.7 
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KPI domain of the homolog was clearly less potent as 
an inhibitor of factor XI, than that of APP. Compared 
to BPTI, however, the affinity of APPH KPI was still 
appreciable. 
Fig. 4 shows an experiment in which factor XI, was 
added to a reaction mixture containing fluorogenic sub- 
strate plus inhibitor. Curve b and c show the resulting 
transient inhibition curves with 20 nM APPH KPI, and 
curve d and e the results with 20 nM APP KPI. The 
activity of factor XI, in the absence of inhibitor (curve 
a) is shown for comparison. As has been previously re- 
ported [6], heparin increased the rate of factor XI, inhibi- 
tion by APP KPI (curve e). The results also indicated 
that heparin induced a similar increase in the rate of 
factor XI, inhibition by APPH KPI (curve c) and by 
BPTI (results not shown). 
4. Discussion 
Unlike seemingly non-inhibitory KPI domains such as 
the domain 3 from TFPI and the domain from the ~(3) 
chain of collagen type VI (unpublished results), the KPI 
domain from APPH is clearly capable of interacting with 
several proteases. In its inhibition profile it resembles 
somewhat hat of the KPI domain from APP. 
Previous studies on APP have revealed that the inhib- 
itory properties of the truncated, secreted form of the 
native molecule [4-81 were similar to those of the individ- 
ual domain expressed in bacteria, yeast and COS-1 cells 
[9-121. We may assume that the same is true for APPH. 
The observation that the APP KPI domain was a po- 
tent inhibitor of trypsin, chymotrypsin, plasmin and no- 
tably Factor XI,, all with inhibitor constants <lo-’ M 
[9-121, has been confirmed by the present work (Table 
1). In addition we have confirmed the observation [9] 
that APP KPI interacts weakly (&-lo-’ M) with plasma- 
and glandular kallikrein. 
APPH KPI inhibits glandular kallikrein with a tenfold 
higher affinity, but inhibits chymotrypsin with a tenfold 
lower affinity than APP KPI (Table 1). It is interesting 
to note that the effect of heparin on factor XI, inhibition 
is not unique to APP [6], but appears to be a rather 
general phenomenon which was also observed with the 
separate KPI domains tested in the present study (Fig. 4). 
Substrate (concentration) 
<Glu-Gly-Arg-pNA (0.6 mM) 
MeO-Sue-Arg-Pro-Tyr-pNA (0.6 mM) 
H-o-Val-Leu-Lys-pNA (0.6 mM) 
H-o-Pro-Phe-Arg-pNA (0.6 mM) 
H-o-Val-Leu-Arg-pNA (0.6 mM) 
Boc-Glu(OBzl)-Ala-Arg-MCA (0.12 mM) 
0.17 
0.082 
0.22 
0.19 
0.21 
0.86 
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Fig. 4. Transient inhibition of factor XI, by APPH KPI and APP KPI 
in the presence and absence of heparin. Factor XI, (3 nM) was added 
to a reaction mixture containing 0.25 mM Boc-Glu(OBzl)-Ala-Arg- 
MCA and 20 nM inhibitor (curve b and c: APPH KPI; curve d and e: 
APP KPI). Heparin (10 &ml) was present in experiments hown as 
curve c and e. The activity of factor XI, in the absence of inhibitor is 
shown for comparison (curve a). The progress curve in fluorescence 
emission at 460 nm (Ex. 380 nm) was followed as a function of time. 
The soluble form of APP was purified from the condi- 
tioned media from HepG2 cells as a factor XI, inhibitory 
activity [6]. The potency of the inhibitor towards factor 
XI,, its activation by heparin, and synthesis in platelets 
and liver-derived cells [6,7] has prompted several abora- 
tories to speculate that the truncated, secreted form of 
APP may play a role in regulation of haemostasis. The 
KPI domain of APPH is highly similar (37/57 identical 
amino acids) to the KPI domain of APP, including 
strong homology of residues of the protease contact re- 
gion. These properties, and also our observation (data 
not shown) that this molecule is transcribed in human 
endothelial cells, make it possible that APPH, like APP, 
could be involved in regulation of the haemostatic bal- 
ance. 
The results of the present study (Table 1, Fig. 3) con- 
firm previous observations [5-71 that the APP KPI do- 
main is indeed a very potent inhibitor of factor XI,, and 
that other serine proteases of the coagulation system 
were not inhibited to an appreciable extend by this do- 
main. 
Results obtained with the separately expressed KPI 
domain (Table 1, Fig. 3) might suggest hat APPH, like 
APP, could in fact function as an inhibitor of factor XI, 
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in vivo. Although the affinity was 20-fold lower than that 
of APP, it is still in the nanomolar, physiological range, 
and factor XI, might therefore serve as a putative ligand 
for APPH. It is likely, however, that the true physiolog- 
ical protease ligand for the APPH receptor molecule has 
still to be identified. 
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